文献速递淋巴瘤

Pevonedistat(NAE抑制剂)对CLL来源T细胞的免疫调节作用

Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
PubMed 文献 · Leukemia · 2020-03-16

本研究探讨NAE抑制剂pevonedistat(TAK-924)对慢性淋巴细胞白血病(CLL)患者T细胞的免疫调节效应。体外实验显示,pevonedistat虽差异化调节NF-κB调控基因并下调IL-2信号,但T细胞可逃避凋亡,且向TH1表型极化、Treg分化减少、干扰素-γ产生增加;免疫健全小鼠模型体内再现上述结果。洗脱实验表明,依据人体药代动力学特征暴露于pevonedistat的T细胞可恢复NAE活性并维持TCR刺激反应及细胞毒潜能。

要点

  • Pevonedistat抑制NAE可差异化调节CLL T细胞NF-κB基因并下调IL-2信号,但不诱导凋亡。
  • Pevonedistat促进T细胞向TH1极化、减少Treg分化并增加干扰素-γ产生。
  • 洗脱后T细胞恢复NAE活性,维持TCR反应和细胞毒潜能。

核心结论

  • 靶向neddylation通路在CLL中具有潜在的免疫调节作用,pevonedistat可有利地调节T细胞极化而不诱导T细胞凋亡。

研究设计与样本

  • 使用CLL患者来源T细胞进行体外实验,并在免疫健全小鼠模型中进行体内验证。
  • 洗脱实验依据pevonedistat的人体药代动力学特征设计。

主要发现

  • 靶向NAE导致T细胞活化期间NF-κB调控基因表达显著差异并下调IL-2信号,但T细胞逃避凋亡。
  • NAE抑制在体外有利地调节T细胞极化,表现为Treg分化减少、向TH1表型偏移并伴干扰素-γ产生增加。
  • 上述发现在免疫健全小鼠模型中再现。
  • 洗脱实验中暴露于pevonedistat的T细胞恢复NAE活性,并维持对T细胞受体刺激的反应和细胞毒潜能。

临床怎么用

  • 提示pevonedistat在CLL治疗中可能保留T细胞免疫功能并增强TH1型免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. We and others have shown that pevonedistat (TAK-924), a small-molecule inhibitor of NAE, abrogates NF-κB signaling in malignant B cells. However, NF-κB pathway activity is indispensable in immune response, and T-cell function is altered in patients with CLL. Using T cells derived from patients with CLL, we demonstrate that although targeting NAE results in markedly differential expression of NF-κB-regulated genes and downregulation of interleukin (IL)-2 signaling during T-cell activation, T cells evade apoptosis. Meanwhile, NAE inhibition favorably modulates polarization of T cells in vitro, with decreased Treg differentiation and a shift toward TH1 phenotype, accompanied by increased interferon-γ production. These findings were recapitulated in vivo in immunocompetent mouse models. T cells exposed to pevonedistat in washout experiments, informed by its human pharmacokinetic profile, recover NAE activity, and maintain their response to T-cell receptor stimulation and cytotoxic potential. Our data shed light on the potential immune implications of targeting neddylation in CLL and lymphoid malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Best S, Lam V, Liu T, et al. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. Leukemia. 2020. PMID: 32203139. doi:10.1038/s41375-020-0794-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。